Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Experimental biological therapy that neutralizes the pro-inflammatory effects of interleukin-2 (IL-2).
Main Inclusion Criteria: Patients aged 18 and older who have been diagnosed with atopic dermatitis for at least one year, have not been on biological therapy before, and, despite receiving at least one line of standard therapy, have not had well-controlled disease or currently do not have well-controlled disease.
Status: In preparation
Start of Patient Enrollment: May 2024.
